Article Text

PDF
Molecular characterisation of six patients with prolidase deficiency: identification of the first small duplication in the prolidase gene and of a mutation generating symptomatic and asymptomatic outcomes within the same family
  1. A Lupi1,
  2. A Rossi1,
  3. E Campari1,
  4. F Pecora1,
  5. A M Lund2,
  6. N H Elcioglu3,
  7. M Gultepe4,
  8. M Di Rocco5,
  9. G Cetta1,
  10. A Forlino1
  1. 1Department of Biochemistry “A Castellani”, Section of Medicine and Pharmacy, University of Pavia, Pavia, Italy
  2. 2Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark
  3. 3Department of Pediatrics Genetics, Marmara University Hospital, Istanbul, Turkey
  4. 4Department of Biochemistry, GATA Haydapasa Training Hospital, Istanbul, Turkey
  5. 5Unit of Rare Diseases, Department of Pediatrics, Gaslini Institute, Largo Gaslini 3, Genoa, Italy
  1. Correspondence to:
 A Forlino
 Department of Biochemistry “A Castellani”, Section of Medicine and Pharmacy, University of Pavia, Via Taramelli 3/B, 27100 Pavia, Italy; aforlino{at}unipv.it

Abstract

Prolidase deficiency (PD) is a rare autosomal recessive connective tissue disorder caused by mutations in the prolidase gene. The PD patients show a wide range of clinical outcomes characterised mainly by intractable skin ulcers, mental retardation and recurrent respiratory infections. Here we describe five different PEPD mutations in six European patients. We identified two new PEPD mutant alleles: a 13 bp duplication in exon 8, which is the first reported duplication in the prolidase gene and a point mutation resulting in a change in amino acid E412, a highly conserved residue among different species. The E412K substitution is responsible for the first reported phenotypic variability within a family with severe and asymptomatic outcomes.

  • PCR, polymerase chain reaction
  • PEPD, prolidase gene

Statistics from Altmetric.com

Footnotes

  • Funding: This work was supported by Fondo di Ateneo per la Ricerca (FAR) and Fondazione Cariplo.

  • Competing interests: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.